ArticleFrontiers in endocrinology2025
Association between glycemia risk index and carotid intima-media thickness in type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between the Glycemic Risk Index (GRI) and carotid intima-media thickness (CIMT) in type 2 diabetes mellitus (T2DM) patients and evaluate the clinical utility of GRI for early vascular risk assessment. Methods: This retrospective study included 450 previously untreated patients with T2DM prior to hospitalization. We calculated GRI using CGM data and assessed CIMT with high-resolution ultrasound. Multiple linear and logistic regression analyses assessed the association between GRI and CIMT. Receiver operating characteristic (ROC) curve analyses evaluated GRI's predictive performance. Results: There was a significant positive correlation between GRI and CIMT (r = 0.42, P < 0.001). After adjusting for confounders, GRI remained an independent predictor of CIMT thickening (OR = 7.226, 95% CI: 5.597-8.856, P < 0.001). ROC analysis revealed that GRI alone predicted abnormal CIMT with an AUC of 0.869. Conclusion: GRI is a robust marker for predicting CIMT thickening in T2DM patients, providing a novel approach for cardiovascular risk stratification. This study underscores the potential of integrating GRI into routine diabetes management to improve vascular outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.